Harry Liu

Harry Liu is an experienced biopharmaceutical executive currently serving as the Vice President of Clinical Development at Asher Biotherapeutics since January 2025. Previously, Harry was the Executive Director of Clinical Development at ALX Oncology from October 2021 to December 2024, where significant contributions included leading a Phase 1 study of evorpacept in bladder cancer and overseeing Phase 2 studies in head and neck squamous cell carcinoma. Prior to ALX Oncology, Harry had a notable tenure at Genentech, where roles included Lead Medical Director for oncology product development, overseeing the clinical lead for various projects including Rozlytrek and the TAPESTRY platform study. Harry's career began at Amgen as a senior manager in drug safety, with earlier positions as a clinical data analyst and research associate. Education includes an MBA in Business Strategy and Finance from UCLA Anderson School of Management, an MD from Jilin University, and an MPH in Epidemiology from the University of California, Berkeley.